Followers | 129 |
Posts | 2150 |
Boards Moderated | 1 |
Alias Born | 12/27/2007 |
Monday, July 15, 2019 7:27:42 AM
ET-202. Eton has initiated launch preparations for ET-202, Eton’s ready-to-use injectable formulation of phenylephrine. If approved on its PDUFA date of October 21, 2019, Eton anticipates launching the product in the fourth quarter of 2019. Eton believes the addressable phenylephrine market for ET-202 is more than 10 million units annually.
ET-103. The bioequivalence study for ET-103, a liquid formulation of levothyroxine, is ongoing. Eton expects study results in September and, if successful, plans to submit the NDA in the fourth quarter of 2019.
ET-203. The NDA for ET-203, a ready-to-use formulation of a high-volume injectable product, is expected to be submitted by Eton’s partner by the end of the third quarter of 2019.
ET-104. The bioequivalence study for ET-104, a patent-pending oral suspension pursuing a neurological indication, is ongoing. Eton expects study results in September and, if successful, plans to submit the NDA in the fourth quarter of 2019.
Recent ETON News
- Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference • GlobeNewswire Inc. • 05/01/2024 08:05:00 PM
- Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution) • GlobeNewswire Inc. • 04/30/2024 11:00:00 AM
- Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024 • GlobeNewswire Inc. • 04/29/2024 08:30:00 PM
- Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria • GlobeNewswire Inc. • 03/22/2024 06:00:00 AM
- Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/14/2024 08:01:00 PM
- Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024 • GlobeNewswire Inc. • 02/29/2024 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 11:55:25 AM
- Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation • GlobeNewswire Inc. • 02/21/2024 11:50:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:21:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:19:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:17:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 11:55:44 AM
- Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules • GlobeNewswire Inc. • 02/02/2024 11:50:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:25:42 PM
- Eton Pharmaceuticals Reports Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/09/2023 09:01:00 PM
- Eton Pharmaceuticals to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023 • GlobeNewswire Inc. • 10/30/2023 10:50:00 AM
- SWK Holdings Highlights Recent Achievements and Provides Portfolio Update • PR Newswire (US) • 10/18/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2023 10:55:16 AM
- Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone • GlobeNewswire Inc. • 10/04/2023 10:50:00 AM
- Eton Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 08/23/2023 10:50:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 08:20:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 08:15:55 PM
- Eton Pharmaceuticals Reports Second Quarter 2023 Financial Results • GlobeNewswire Inc. • 08/10/2023 08:01:00 PM
- Eton Pharmaceuticals to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023 • GlobeNewswire Inc. • 08/01/2023 08:05:00 PM
- SWK Holdings Highlights Recent Achievements and Provides Portfolio Update • PR Newswire (US) • 07/17/2023 08:05:00 PM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM